Predictmedix is an artificial intelligence company developing disruptive and cutting-edge tools for impairment testing and health care.

1. Disruptive technologies for impairment and healthcare
predictmedix.com
PMED : CSE PMEDF : OTCQB

2. DISCLAIMER
COMPLETE DISCLAIMER IN INVESTMENT MEMORANDUM
This document provides a summary description of PREDICTMEDIX Inc. (“PREDICTMEDIX”), its subsidiary companies and its business and does not purport to be complete. Prospective investors are
encouraged to obtain independent legal advice concerning any investment in securities of PREDICTMEDIX and should not base their decision on whether to invest in PREDICTMEDIX upon the material
provided herein. There are no representations or warranties made herein by PREDICTMEDIX or the agents of the proposed offering of units of PREDICTMEDIX (the “Agents”) and investors will only be
able to rely on the representations and warranties contained in the subscription agreement to be entered into at the time of sale of the securities. This document is strictly confidential and has been
prepared solely for use in connection with the offering of the securities described herein.
Neither this document nor any of its contents are to be distributed to third parties without the prior written consent of PREDICTMEDIX and its Agents. There are certain risks inherent in an investment in
the securities of PREDICTMEDIX which prospective investors should carefully consider before investing in the securities of PREDICTMEDIX. This document constitutes an offering of the securities
described herein only in those jurisdictions and to those persons where and to whom they may be lawfully offered for sale, and only by persons permitted to sell these securities. This document is not,
and under no circumstances is it to be construed as, an advertisement or a public offering of these securities. This document is personal to each offeree and does not constitute an offer to any other
person or to the public generally to subscribe for or otherwise acquire any of the securities referred to herein. No securities regulatory authority or similar authority has reviewed or in any way passed
upon the document or the merits of these securities and any representation to the contrary is an offence.
This document has been prepared for information purposes only in order to assist prospective investors in evaluating an investment in PREDICTMEDIX. By accepting delivery of this document or any
other information in connection with an investment in PREDICTMEDIX, the investor agrees: (1) to keep strictly confidential the contents of this presentation and such other information and not to disclose
such document, the contents thereof or any such information to any third party or otherwise use the information for any purpose other than evaluation by such prospective investor/offeree of an
investment in the securities; (2) not to copy all or any portion of this document, or any such other information; and (3) to return this document and all such other documents and information to
PREDICTMEDIX or the Agents upon the request of PREDICTMEDIX or the Agents.
No representation, warranty or undertaking, expressed or implied, is made and no responsibility or liability is accepted by the Agents as to the accuracy or completeness of the information contained
herein or any other information, representation, warranty or undertaking, express or implied, made by PREDICTMEDIX in connection with the offering of securities described herein.
FORWARD-LOOKING INFORMATION
This investor document contains statements that, to the extent that they are not historical fact, may constitute “forward-looking statements” within the meaning of applicable securities legislation. Any
statements regarding future plans, objectives or economic performance of PREDICTMEDIX, or the assumption underlying any of the foregoing, constitute forward-looking information. This investor
document uses words such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, and other similar expressions to identify
forward-looking statements. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this investor document, and,
accordingly, investors should not place undue reliance on any such forward-looking statements. Forward-looking information involves significant risks, assumptions, uncertainties and other factors that
may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements and accordingly, should not be read as guarantees of future
performance or results. Any forward-looking statements speak only as of the date on which such statement is made and each of PREDICTMEDIX and the Agents disclaims any intention or obligation to
update or revise any forward-looking information, where as a result of new information, future events or otherwise, unless required by applicable law. New factors emerge from time to time, and it is not
possible for management to predict all of such factors and to assess in advance the impact of each such factor on PREDICTMEDIX’s business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements.
The Company reserves the right to request the return of the Information at any time.
2PMED : CSE PMEDF : OTCQB

3. Drug & Alcohol
Impairment
Infectious
Disease
Mental
Illness
3
PREDICTMEDIX is an Artificial Intelligence company developing disruptive technologies for impairment and
healthcare.
PREDICTMEDIX AI powered products use facial, thermal, video and audio recognition technologies to
determine when individuals are impaired, suffering from infectious disease or mental illness.
PREDICTMEDIX products are developed and owned by PREDICTMEDIX Inc. A Canadian Public Company
trading on exchanges in Canada and the USA.
predictmedix.com
FROM INDIVIDUAL TESTING TO RAPID MASS SCREENING
WHO WE ARE
READING THE SIGNS BEFORE THE CONSEQUENCES
PMED : CSE PMEDF : OTCQBB

4. SOLUTIONS
CANNABIS & ALCOHOL IMPAIRMENT
Employers, as well as law enforcement,
screen people for traces of cannabis, alcohol
and opioids. However, they cannot
determine if individuals are actually
impaired.
Without the ability to determine impairment,
it is not possible to accurately predict safety
risk.
The latest US Congressional report indicates
that testing biologics through breath and
bodily fluids, such as blood, urine and saliva,
will not determine impairment. Furthermore,
breath testing will not identify impairment
from edible cannabis or opioids taken orally.
This has major implications due to medicinal
use of cannabis and opioids, in particular.
Rather then test for traces of substances,
PREDICTMEDIX uses facial and audio
recognition technologies to screen for
impairment due to substances.
Quick, non-invasive, contactless screening that
requires very little training to administer
Deploys easily in any workplace and easy to use
for law enforcement officials
First solution to identify impairment and no need for
any biologics
PREDICTMEDIX first-to-market AI product screens for
Cannabis impairment.
The PREDICTMEDIX AI model is being expanded to
include screening for alcohol and opioids.
FIRST-TO-MARKET
4PMED : CSE PMEDF : OTCQBB

5. Quick, non-invasive, contactless screening that
requires very little training to administer
Deploys easily in any workplace, healthcare facility
for mass screening
Eliminates the need for biologics, protecting
screeners from exposure to infectious disease
COVID-19 reminds us of the need for rapid
mass screening and instant results to quickly
and reliably identify infectious diseases.
Current testing tools, such as saliva swabs
and blood draws, are invasive for patients and
expose workers to infection.
Infections produce unique physiological
patterns:
• Temperature variances on face and body
• Eye redness
• Coughing and sneezing
PREDICTMEDIX physiological recognition
technology can potentially be used as a rapid
mass screening tool for COVID-19. As well as
for other infectious diseases.
Its utility becomes critical even after the
current pandemic subsides. Experts agree
outbreaks will revive in waves. By deploying
PREDICTMEDIX virtually anywhere, we
detect infections and analyze hot spot
locations early. Giving Public Health
authorities the ability to proactively
protect populations.
PREDICTMEDIX can be deployed in settings outside of
hospitals and healthcare facilities.
Airports, malls, stadiums, government and office
buildings. Any location where people gather or where
transmission security is paramount.
RAPID MASS SCREENING
5PMED : CSE PMEDF : OTCQBB
SOLUTIONS
INFECTIOUS DISEASE

6. Quick, non-invasive, contactless screening that
requires very little training to administer
Deploys easily in any workplace, healthcare facility
or indoor/outdoor environment
Eliminates the need for biologics, protecting
screeners from exposure to infectious disease
When people suffering brain disorders go
untreated, they can become dangers to others
and themselves. Particularly in jobs where
safety and cognition are critical factors.
Mental illness is difficult to detect at early
stages.
Depression, dementia and other brain
disorders are often dismissed or hidden, due
to societal stigma and lack of simple
diagnostic tools.
Most mental illness diagnosis is subjective,
unreliable and unfortunately there are no
blood tests for majority of mental health
disorders.
PREDICTMEDIX uses facial, video and audio
patterns to effectively determine signs of
mental illnesses, including depression,
dementia and other brain disorders.
PREDICTMEDIX deployed in healthcare
facilities and medical offices will provide
practitioners with a simple, measurable
diagnostic tool to detect signs of
these disorders at early stages.
PREDICTMEDIX is a disruptive AI technology that can
detect signs of mental illness at early stages. Giving
healthcare practitioners the opportunity to provide proper
care before their patient’s condition worsens.
It is expected that workplaces will also use
PREDICTMEDIX to protect and care for the mental
health of their workforce.
EARLY STAGE DIAGNOSIS
6PMED : CSE PMEDF : OTCQBB
SOLUTIONS
MENTAL ILLNESS

7. PREDICTMEDIX utilizes existing data capture hardware already
in operation in many healthcare facilities and by law
enforcement departments throughout North America. The
devices are small and easily implemented in any workplace
environment.
PREDICTMEDIX AI models interpret data and deliver diagnostic
results.
We operate on a cloud-based platform, communicating with
devices and delivering results in real time.
Clients pay a monthly fee based on volume of screenings per
use case. Providing PREDICTMEDIX with recurring monthly
revenue and multi-year contracts.
Volume tiered pricing will allow clients to scale appropriately for
their needs.
7PMED : CSE PMEDF : OTCQBB
BUSINESS MODEL
INDIVIDUAL TESTING TO RAPID MASS SCREENING
Drug & Alcohol
Impairment
Infectious
Disease
Mental
Illness
Individual Cluster
Thermal RGB Audio-Video Mapping
SCREENING
RESULTS

8. GLOBAL MARKET
Significant global events and societal shifts are driving the need for expanded
screening capability and faster results.
None more apparent today than the COVID-19 pandemic. This situation will
accelerate the response to healthcare professionals’ demand to implement early
screening mechanisms for many types of infectious diseases.
Drug & Alcohol screening in work environments is becoming more urgent due to
legalization of cannabis. Medicinal use of cannabis, as well as opioids, pose a serious
liability risk to companies and their insurers. As well as continuing to be a high priority
for law enforcement.
The recognition of mental illness has become a front-and-centre issue in society.
Early treatment is essential to limit or eliminate the impact on individuals, families and
employers.
USD$13.9 Billion Drug Screening Market Forecast for 2027
USD$5 Billion Respiratory Disease Screening Market in 2016
USD$2.1 Billion Behavioral & Mental Healthcare Software Market in 2019
USD$1.4 Billion Cannabis Screening Market Forecast for 2021
USD$13 Billion AI in Healthcare Market Size for 2025
8PMED : CSE PMEDF : OTCQBB
MARKET & COMPETITORS
OUR COMPETITIVE LANDSCAPE
Existing competitors are varied and continue to work primarily on advancing
technologies that use biologics, including breath and bodily fluids analysis.
In contrast, PREDICTMEDIX, focuses its development on disruptive
technologies to eliminate or moderate the need for biologics.
This reduces waiting time for test results and accelerates the ability of
employers, healthcare and law enforcement to rapidly screen mass
numbers of people.
According to public disclosures, both companies utilize biologics and neither
company determines impairment, which is what PREDICTMEDIX delivers.
Cannabix is developing tools for
law enforcement and the
workplace to detect THC in
breath.
The Hound® Marijuana
Breathalyzer measures recent
marijuana use and alcohol in a
person’s breath.

9. THE BIGGEST AND BEST
BELIEVE IN OUR SOLUTION
PREDICTMEDIX has signed Joint Venture agreements with Tech
Mahindra and Hindalco for PREDICTMEDIX Cannabis and Alcohol
screening technology.
Both companies recognize the value of testing for impairment in work
environments such as mining, manufacturing and automotive sectors.
Tech Mahindra will resell PREDICTMEDIX to their global client base,
having already participated in a successful pilot test with our team.
Hindalco will begin by deploying PREDICTMEDIX cannabis and alcohol
impairment screening in their mining division. Then expand to their other
worldwide business divisions.
Indian Institute of Technology (IIT) is renowned for training the world’s
top technology engineers. Our strategic partnership with IIT provides us
with talented engineers and AI specialists who work with our senior team
to develop platform functionality and AI screening models.
9PMED : CSE PMEDF : OTCQBB
PARTNERSHIPS
OUR PATH TO SUCCESS
Tech Mahindra
Ranked among top 15 global IT companies by Forbes.
$4.9 billion dollar company owned by Mahindra
Group, a $420.7 billion dollar federation of
companies.
Hindalco Industries
The worldwide industry leader in aluminium and
copper. Hindalco is the metals flagship company of
Aditya Birla Group, with a consolidated annual
revenue of $18.7 billion.
Indian Institute of Technology (IIT)
Globally top ranked engineering school whose alumni
include CEO’s and CTO’s of many Fortune 500
companies including Google, IBM and Microsoft.

10. 10
DR. RAHUL KUSHWAH
COO
• PhD, Banting Fellow (one of 23 global recipients in medicine)
• Developed world’s first genetic test for cannabis pharmacogenetics
• Previously on the National Research Council for the Government
of Canada in Human Health Therapeutics
• Expertise in human diseases, genetics, immunology and
regenerative / personalized medicine
NANDAN MISHRA
AI Lead
• Artificial Intelligence pioneer in translational research for AI
• Masters in Systems Biology and Bachelors Degree in Engineering
from the Indian Institute of Technology
• Member of the prestigious National Mission of Interdisciplinary
Cyber Physical Systems of India (a federal technology think tank)
HIMANSHU UJJAWAL SINGH
Co-AI Lead
• Specialization in Data Analytics and AI
• Consulted with several multinational corporations in setting up their
analytics practice in the field of telecom, healthcare, retail and
workforce analytics
• Expertise in data monetization
PRAVEEN KUMAR
Data Analytics Lead
• Specialization in Data Analytics, Machine Learning and Deep
Neural Networks
• Worked with several top Fortune 500 companies
• Consulted with top financial corporations in Canada
SHELDON KALES
CEO
• Expertise in operations, business strategy and capital markets
• Has held leadership roles operating R&D companies in the USA,
Canada and the Middle East
• Led companies from start-up stages through growth and successful
exits
PMED : CSE PMEDF : OTCQBB
LEADERSHIP TEAM
RAKESH MALHOTRA
CFO
• CPA designation in US and Canada, FCA
• Over 25 years in accounting, financing and internal controls
• Has held senior management positions in publicly traded
companies

11. 11
DR. RAHUL KUSHWAH
• PhD, Banting Fellow
• Developed world’s first genetic test for cannabis
pharmacogenetics
• Previously on the National Research Council for the
Government of Canada in Human Health
Therapeutics
• Expertise in human diseases, genetics, immunology
and regenerative / personalized medicine
AJIT KUMAR
• Seasoned healthcare business leader
• Founder of K-Med Ltd.; among the largest suppliers
of healthcare and medical equipment in the UK with
operations in the Middle East, EU and Africa
PMED : CSE PMEDF : OTCQBB
BOARD OF DIRECTORS & ADVISORS
TOMAS SIPOS
• Seasoned investment banker
• Has held several senior positions, including VP,
Mergers and Acquisitions of Ernst & Young,
Managing Director of Investment Banking at
European Privatization & Investment Corporation
and Senior Investment Banker for the International
Finance Corporation
• Presently, CFO for Pistil Partners Inc., and serves
as a director of NATO Association of Canada
Program Committee
DR. DAWN DECUNHA
• Clinical Psychologist and educator
• Specialty in emotional trauma, psychiatric and
psychological trauma
DR. TALLY BODENSTEIN PhD
• Practicing psychologist for over 20 years
• Speciality in children, adolescents and families
DR. INDRANIL SAHA PhD
• Assistant Professor, Computer Science &
Engineering, IIT
• Expert in the areas of Artificial Intelligence and
Robotics
• Received the ACM SIGBED Frank Anger Memorial
Award in 2012 for his contribution in the intersection
of embedded systems and software engineering
DR. MIKE HART MD
• Early adopter of medicinal marijuana applications in
medical practice, opening first of its kind facility in
London, Ontario
• “Expert” guest on the subject of medicinal
marijuana, appearing on CTV news, Rogers TV,
CBC National Radio, Toronto Star and Canadian
Consortium for the Investigation of Cannabinoids
DR. NITIN KADAM MBBS, DCH, MD
• Professor at M.G.M. Medical College Mumbai
• Management team member for M.G.M. group of
colleges and hospitals
• Director of M.G.M.’s New Bombay Hospital
• Management Council Member, M.G.M. University of
Health Sciences, Academic Council & Board of
Studies
DR. ALEXANDER D. BARRON CCFP(EM)
• Emergency Room physician for over 6 years
• Expertise in infectious disease and screening
• Works in 3 different hospital emergency
departments: Norfolk General, St. Mary’s General
and Grand River Hospital
• Associate Clinical Professor at McMaster University
DR. BORHANE GUEZGUES MSc, PhD
• PhD in Immunology, Post Doctoral experience
focused on Stem Cells and Hematology
• Expertise in genetic and epigenetic deregulations in
hematologic malignancies and leukemia
• Identified clinical genetic signatures for
hematological malignancies
DR. NAVDEEP SINGH NANDA MBBS, MS, DNB
• One of India’s leading thoracic surgeons, practicing
in BLK Super Speciality Hospital, the largest stand-
alone private sector hospital in India
• Immense experience in the field of thoracic surgery,
thoracic oncology, VATS, robotic chest surgery and
related research
BOARD MEMBERS

12. 12
Authorized Capital Unlimited
Shares Issued & Outstanding 100,054,149*
Incentive Stock Options 9,850,000 @ $0.15 Expiry: April 6, 2021
350,000 @ $0.10
Warrants 1,648,000 @ $0.50 Expiry: August 2021
Fully Diluted Shares 111,902,149
Most recent financing 3,296,000 @ $0.25
*Includes 42,682,500 shares held in escrow
PMED : CSE PMEDF : OTCQBB
CAPITAL STRUCTURE

13. The Board of Directors and management
team believe the growing need for rapid,
mass, early stage screening is critical for
governments, healthcare, law enforcement,
and employers worldwide.
We also believe that the heightened
environment of anxiety caused by the COVID-
19 pandemic will accelerate adoption of these
technologies.
Particularly for disruptive AI powered
technologies such as PREDICTMEDIX that
eliminate the need for biologics and can be
deployed virtually anywhere, at reasonable
fees, with very little training required by users.
13PMED : CSE PMEDF : OTCQBB
FUTURE OUTLOOK
2 0 2 0
Drug & Alcohol Impairment
Completion of study with over 3,000 participants
Dissemination of study in peer reviewed engineering journals
Pilots with Hindalco and Tech Mahindra
Launch of product for workplace safety impairment screening
Infectious Disease
US patent filing
COVID-19 pilots in healthcare facilities
COVID-19 pilots in locations with high volumes of people
Launch of product for infectious disease screening
Mental Illness
US patent filing

14. PMED : CSE PMEDF : OTCQB
predictmedix.com
Dr. Rahul Kushwah, COO
Rahul.kushwahphd@gmail.com
1 (647) 889-6916
Disruptive technologies for impairment and healthcare
CORPORATE INFORMATION INVESTOR RELATIONS
77 King Street West, Suite 3000
Toronto, ON, Canada M5K 2A1